EE05378B1 - LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks - Google Patents
LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseksInfo
- Publication number
- EE05378B1 EE05378B1 EEP200300004A EEP200300004A EE05378B1 EE 05378 B1 EE05378 B1 EE 05378B1 EE P200300004 A EEP200300004 A EE P200300004A EE P200300004 A EEP200300004 A EE P200300004A EE 05378 B1 EE05378 B1 EE 05378B1
- Authority
- EE
- Estonia
- Prior art keywords
- molecule
- soluble
- preparation
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21591300P | 2000-07-03 | 2000-07-03 | |
PCT/US2001/021204 WO2002002638A2 (en) | 2000-07-03 | 2001-07-02 | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200300004A EE200300004A (et) | 2004-10-15 |
EE05378B1 true EE05378B1 (et) | 2011-02-15 |
Family
ID=22804919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300004A EE05378B1 (et) | 2000-07-03 | 2001-07-02 | LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks |
Country Status (39)
Country | Link |
---|---|
US (1) | US7455835B2 (de) |
EP (4) | EP1935427B1 (de) |
JP (1) | JP2004517806A (de) |
KR (3) | KR100864120B1 (de) |
CN (1) | CN1318086C (de) |
AR (2) | AR035037A1 (de) |
AT (1) | ATE401909T1 (de) |
AU (2) | AU2001273174B2 (de) |
BG (2) | BG66024B1 (de) |
BR (1) | BR0112104A (de) |
CA (2) | CA2630062C (de) |
CY (3) | CY1109786T1 (de) |
CZ (1) | CZ303959B6 (de) |
DE (1) | DE60135029D1 (de) |
DK (2) | DK1372696T3 (de) |
EE (1) | EE05378B1 (de) |
ES (2) | ES2310557T3 (de) |
HK (1) | HK1058486A1 (de) |
HR (1) | HRP20030071B1 (de) |
HU (3) | HU227669B1 (de) |
IL (2) | IL153593A0 (de) |
IS (1) | IS2834B (de) |
LT (2) | LT1935427T (de) |
LV (1) | LV12993B (de) |
MX (1) | MXPA02012603A (de) |
MY (1) | MY137552A (de) |
NO (3) | NO20026264L (de) |
PE (1) | PE20020772A1 (de) |
PL (2) | PL212205B1 (de) |
PT (2) | PT1935427T (de) |
RS (1) | RS50811B (de) |
RU (1) | RU2287340C2 (de) |
SI (3) | SI1935427T1 (de) |
SK (1) | SK287940B6 (de) |
TR (1) | TR201807700T4 (de) |
TW (2) | TWI311564B (de) |
UY (1) | UY26815A1 (de) |
WO (1) | WO2002002638A2 (de) |
ZA (1) | ZA200210058B (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
IL125928A (en) * | 1996-03-20 | 2002-11-10 | Bristol Myers Squibb Co | The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
UA87432C2 (uk) * | 2000-05-26 | 2009-07-27 | Бристол-Майерс Сквибб Компани | Розчинний мутантний ctla4 та його застосування |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
EP1935427B1 (de) | 2000-07-03 | 2018-03-07 | Bristol-Myers Squibb Company | Verwendung von löslichen mutanten CTLA4-Mutantenmolekülen |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
EP1368059A1 (de) * | 2001-01-26 | 2003-12-10 | Emory University | Methoden zur induktion der organstransplantat-toleranz und zur korrektur von hämoglobinopathien |
WO2002094202A2 (en) * | 2001-05-23 | 2002-11-28 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
AU2003243152A1 (en) * | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
JP4541157B2 (ja) * | 2002-12-23 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質を製造するための哺乳類細胞培養法 |
SI1576182T2 (sl) * | 2002-12-23 | 2020-07-31 | Bristol-Myers Squibb Company | Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev |
CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
RU2353384C2 (ru) | 2003-08-04 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4 |
EP1684791A4 (de) | 2003-10-27 | 2009-07-01 | Amgen Inc | Zusammensetzungen und verfahren zur modulierung einer immunantwort auf ein immunogenes therapeutisches mittel |
US7815765B2 (en) * | 2004-04-01 | 2010-10-19 | Swei Mu Wang | Method for forming laminated synthetic leather |
US8476239B2 (en) * | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
ES2439641T3 (es) * | 2005-12-20 | 2014-01-24 | Bristol-Myers Squibb Company | Composiciones y procedimientos de producción de una composición |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
AU2012202324B2 (en) * | 2007-11-01 | 2014-08-28 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
AU2014250683B2 (en) * | 2007-11-01 | 2015-11-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
PL2222697T3 (pl) | 2007-11-01 | 2013-05-31 | Astellas Pharma Inc | Immunosupresyjne polipeptydy i kwasy nukleinowe |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
WO2010033878A2 (en) | 2008-09-19 | 2010-03-25 | David Brown | Solute concentration measurement device and related methods |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
RU2506311C2 (ru) * | 2008-10-30 | 2014-02-10 | Йеда Рисёрч Энд Девелопмент Ко. Лтд. | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний |
US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN102030828B (zh) * | 2009-09-25 | 2014-10-29 | 上海抗体药物国家工程研究中心有限公司 | 一种高亲和力的CTLA4-Ig融合蛋白突变体 |
ES2826894T3 (es) * | 2010-02-19 | 2021-05-19 | Xencor Inc | Nuevas inmunoadhesinas CTLA4-IG |
KR20130049775A (ko) * | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ctla4 단백질 및 이의 용도 |
WO2011146395A2 (en) | 2010-05-17 | 2011-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
EP2614083A2 (de) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | Immunsuppresive wirkstoffkombination für stabiles und langfristiges anwachsen |
KR101788826B1 (ko) | 2010-09-08 | 2017-10-20 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 항-백혈병/림프종 치료를 위한 항 서드파티 중앙 기억 t 세포의 용도 |
WO2013010537A1 (en) * | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
MX351226B (es) | 2011-09-08 | 2017-10-05 | Yeda Res & Dev | Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades. |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN104519900A (zh) | 2012-06-27 | 2015-04-15 | 欧尔本生物科技有限责任公司 | 用于治疗糖尿病的ctla4融合蛋白 |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
WO2014151230A2 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
EP3134109A1 (de) | 2014-04-25 | 2017-03-01 | Bristol-Myers Squibb Company | Verwendung einer ctla4-verbindung zur erzielung einer arneimittelfreien remission bei personen mit früher ra |
KR20180012260A (ko) | 2015-04-17 | 2018-02-05 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 조율가능한 친화성을 갖는 면역조절 단백질 |
PL3322424T3 (pl) | 2015-07-16 | 2024-03-04 | Yeda Research And Development Co., Ltd. | Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej |
EP3192805A1 (de) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitoren von t-zellaktivierung oder stimulation und verwendungen davon |
SG11201808783XA (en) | 2016-04-15 | 2018-11-29 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
US11555178B2 (en) | 2017-01-18 | 2023-01-17 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
MA50404A (fr) | 2017-10-18 | 2020-08-26 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées |
EP3765065A2 (de) | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Von sekretogranin v abgeleitete, antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1 |
WO2019175381A1 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
MX2021008525A (es) | 2019-01-15 | 2021-11-12 | Univ Nantes | Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. |
WO2023112992A1 (ja) * | 2021-12-16 | 2023-06-22 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644792A (en) * | 1899-09-14 | 1900-03-06 | Stanhope Boal | Heater. |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US5521288A (en) * | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE170562T1 (de) | 1991-06-27 | 1998-09-15 | Bristol Myers Squibb Co | Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen |
US5624823A (en) * | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
US5958403A (en) | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
ATE272708T1 (de) | 1992-04-07 | 2004-08-15 | Univ Michigan | Immunregulation über die cd28-route |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
DK0700430T3 (da) | 1993-06-04 | 2005-08-15 | Us Navy | Fremgangsmåder til selektivt af stimulere proliferation af T-celler |
AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
ES2143553T3 (es) | 1993-09-02 | 2000-05-16 | Dartmouth College | Anticuerpos anti-gp39 y sus utilizaciones. |
WO1995015159A1 (fr) | 1993-12-01 | 1995-06-08 | Sankyo Company, Limited | Inhibiteur de la production de cytokines inflammatoires, contenant un derive polyprenyle comme principe actif |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
AU1333195A (en) | 1994-06-03 | 1996-01-04 | Dana-Farber Cancer Institute | Methods for selectively stimulating proliferation of t cells |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
CA2191733A1 (en) | 1994-06-07 | 1995-12-21 | Daniel A. Vallera | Methods for inhibiting antigen specific t cell responses |
US5634055A (en) * | 1994-09-27 | 1997-05-27 | Bidplus, Inc. | Method for selecting assignments |
WO1996014865A1 (en) | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
US5993800A (en) | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
IL125928A (en) | 1996-03-20 | 2002-11-10 | Bristol Myers Squibb Co | The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations |
JPH1067653A (ja) * | 1996-06-17 | 1998-03-10 | Eisai Co Ltd | 関節疾患治療剤 |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
CA2291338A1 (en) | 1997-06-11 | 1998-12-17 | Wisconsin Alumni Research Foundation | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
EP0947524A1 (de) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Neue Peptide zur Behandlung von Autoimmunkrankheiten |
WO1999051275A2 (en) * | 1998-04-03 | 1999-10-14 | Osiris Therapeutics, Inc. | Mesenchymal stem cells as immunosuppressants |
WO1999062525A1 (en) * | 1998-06-05 | 1999-12-09 | Supergen, Inc. | Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis |
JP2000086519A (ja) * | 1998-09-17 | 2000-03-28 | Mitsui Chemicals Inc | 抗リウマチ薬効果増強剤 |
IL126681A0 (en) | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
WO2001090122A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ctla4 gene |
UA87432C2 (uk) * | 2000-05-26 | 2009-07-27 | Бристол-Майерс Сквибб Компани | Розчинний мутантний ctla4 та його застосування |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
EP1935427B1 (de) * | 2000-07-03 | 2018-03-07 | Bristol-Myers Squibb Company | Verwendung von löslichen mutanten CTLA4-Mutantenmolekülen |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
EP1368059A1 (de) * | 2001-01-26 | 2003-12-10 | Emory University | Methoden zur induktion der organstransplantat-toleranz und zur korrektur von hämoglobinopathien |
WO2002094202A2 (en) * | 2001-05-23 | 2002-11-28 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
-
2001
- 2001-07-02 EP EP08001340.2A patent/EP1935427B1/de not_active Expired - Lifetime
- 2001-07-02 TW TW090116137A patent/TWI311564B/zh not_active IP Right Cessation
- 2001-07-02 AT AT01952420T patent/ATE401909T1/de active
- 2001-07-02 DK DK01952420T patent/DK1372696T3/da active
- 2001-07-02 DE DE60135029T patent/DE60135029D1/de not_active Expired - Lifetime
- 2001-07-02 EE EEP200300004A patent/EE05378B1/xx active Protection Beyond IP Right Term
- 2001-07-02 WO PCT/US2001/021204 patent/WO2002002638A2/en active Application Filing
- 2001-07-02 TR TR2018/07700T patent/TR201807700T4/tr unknown
- 2001-07-02 JP JP2002507889A patent/JP2004517806A/ja active Pending
- 2001-07-02 CA CA2630062A patent/CA2630062C/en not_active Expired - Lifetime
- 2001-07-02 RS YUP-1011/02A patent/RS50811B/sr unknown
- 2001-07-02 KR KR1020087005505A patent/KR100864120B1/ko active IP Right Grant
- 2001-07-02 AU AU2001273174A patent/AU2001273174B2/en not_active Expired
- 2001-07-02 HU HU0900660A patent/HU227669B1/hu unknown
- 2001-07-02 ES ES01952420T patent/ES2310557T3/es not_active Expired - Lifetime
- 2001-07-02 SI SI200131067T patent/SI1935427T1/en unknown
- 2001-07-02 KR KR10-2003-7000018A patent/KR20030017606A/ko active Application Filing
- 2001-07-02 CZ CZ20024261A patent/CZ303959B6/cs not_active IP Right Cessation
- 2001-07-02 UY UY26815A patent/UY26815A1/es not_active Application Discontinuation
- 2001-07-02 CN CNB018122299A patent/CN1318086C/zh not_active Expired - Lifetime
- 2001-07-02 SK SK1774-2002A patent/SK287940B6/sk not_active IP Right Cessation
- 2001-07-02 TW TW097137769A patent/TWI322153B/zh not_active IP Right Cessation
- 2001-07-02 BR BR0112104-9A patent/BR0112104A/pt not_active Application Discontinuation
- 2001-07-02 EP EP10184596.4A patent/EP2281568A3/de not_active Withdrawn
- 2001-07-02 SI SI200130864T patent/SI1372696T1/sl unknown
- 2001-07-02 EP EP18158752.8A patent/EP3384924A1/de not_active Withdrawn
- 2001-07-02 ES ES08001340.2T patent/ES2667203T3/es not_active Expired - Lifetime
- 2001-07-02 PT PT80013402T patent/PT1935427T/pt unknown
- 2001-07-02 US US09/898,195 patent/US7455835B2/en not_active Expired - Lifetime
- 2001-07-02 AU AU7317401A patent/AU7317401A/xx active Pending
- 2001-07-02 PL PL389002A patent/PL212205B1/pl unknown
- 2001-07-02 EP EP01952420A patent/EP1372696B1/de not_active Expired - Lifetime
- 2001-07-02 CA CA002413190A patent/CA2413190C/en not_active Expired - Lifetime
- 2001-07-02 LT LTEP08001340.2T patent/LT1935427T/lt unknown
- 2001-07-02 HU HU0301727A patent/HU226847B1/hu active Protection Beyond IP Right Term
- 2001-07-02 IL IL15359301A patent/IL153593A0/xx unknown
- 2001-07-02 MY MYPI20013159A patent/MY137552A/en unknown
- 2001-07-02 AR ARP010103156A patent/AR035037A1/es active IP Right Grant
- 2001-07-02 RU RU2003103098/14A patent/RU2287340C2/ru active
- 2001-07-02 MX MXPA02012603A patent/MXPA02012603A/es active IP Right Grant
- 2001-07-02 SI SI200120046A patent/SI21078A/sl not_active IP Right Cessation
- 2001-07-02 PL PL365942A patent/PL207534B1/pl unknown
- 2001-07-02 PT PT01952420T patent/PT1372696E/pt unknown
- 2001-07-02 KR KR1020087019039A patent/KR100895552B1/ko active Protection Beyond IP Right Term
- 2001-07-02 DK DK08001340.2T patent/DK1935427T3/en active
- 2001-11-14 PE PE2001001131A patent/PE20020772A1/es not_active Application Discontinuation
-
2002
- 2002-12-06 BG BG107362A patent/BG66024B1/bg unknown
- 2002-12-11 ZA ZA2002/10058A patent/ZA200210058B/en unknown
- 2002-12-23 IL IL153593A patent/IL153593A/en active IP Right Grant
- 2002-12-27 NO NO20026264A patent/NO20026264L/no not_active Application Discontinuation
-
2003
- 2003-01-02 IS IS6667A patent/IS2834B/is unknown
- 2003-01-07 LT LT2003002A patent/LT5063B/lt not_active IP Right Cessation
- 2003-02-03 HR HRP20030071AA patent/HRP20030071B1/hr not_active IP Right Cessation
- 2003-02-03 LV LVP-03-08A patent/LV12993B/en unknown
-
2004
- 2004-02-25 HK HK04101364.2A patent/HK1058486A1/xx not_active IP Right Cessation
-
2008
- 2008-05-09 AR ARP080101975A patent/AR066511A2/es unknown
- 2008-10-21 CY CY20081101167T patent/CY1109786T1/el unknown
- 2008-11-05 CY CY2008017C patent/CY2008017I2/el unknown
-
2010
- 2010-03-05 BG BG110611A patent/BG66454B1/bg unknown
- 2010-04-22 NO NO20100579A patent/NO20100579L/no unknown
- 2010-04-22 NO NO20100580A patent/NO20100580L/no not_active Application Discontinuation
- 2010-04-27 HU HUS1000008C patent/HUS1000008I1/hu unknown
-
2018
- 2018-05-23 CY CY20181100546T patent/CY1120577T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05378B1 (et) | LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks | |
DK1524266T3 (da) | Farmaceutisk sammensætning | |
ITTO20010008A0 (it) | Formulazione farmaceutica | |
FI20105657A (fi) | Farmaseuttisia koostumuksia | |
AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
DE60106623D1 (de) | Neue pharmazeutische zusammensetzung | |
ITMI20010748A0 (it) | Composizioni farmaceutiche | |
NO20015175L (no) | Farmasöytisk sammensetning | |
NO20025450L (no) | Ny farmasöytisk sammensetning | |
DK1158992T3 (da) | Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer | |
AT7729U3 (de) | Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat | |
NO20024175L (no) | Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene | |
PT1242087E (pt) | Composicoes farmaceuticas | |
EE200200393A (et) | Glüburiidi ravimkoostis | |
NO20026123L (no) | Farmasöytiske sammensetninger | |
PT1239832E (pt) | Composicoes farmaceuticas | |
ATE366128T1 (de) | Pharmazeutische zusammensetzung | |
DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
DK1227817T3 (da) | Ciclesonid-holdigt vandigt farmaceutisk præparat | |
FI4488U1 (fi) | Farmaseuttinen koostumus | |
AR025867A1 (es) | Formulacion portasdora farmaceutica | |
DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
EE200200689A (et) | Ravimkoostised | |
SE0001541L (sv) | Minoxidil-innehållande farmaceutisk beredning för topikalt bruk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA1Y | Spc filed |
Free format text: PRODUCT NAME: ORENCIA - ABATACEPT; REG NO/DATE: C(2007)2236 21.05.2007 Spc suppl protection certif: C20110002 Filing date: 20110303 |
|
HE1A | Change of address | ||
FG1Y | Spc granted |
Free format text: PRODUCT NAME: ORENCIA - ABATACEPT; REG NO/DATE: C(2007)2236 21.05.2007 C(2010)407 CORR 20.01.2010 Spc suppl protection certif: C20110002 00041 Filing date: 20110303 Extension date: 20221121 |